An­oth­er PhI­II #fail for Bris­tol-My­ers’ star drug rais­es fresh ques­tions about their R&D strat­e­gy as Mer­ck surges fur­ther ahead

Bris­tol-My­ers Squibb $BMY has a fresh Phase III set­back to re­port to­day on its all-im­por­tant PD-1 drug Op­di­vo. The phar­ma gi­ant says that their drug com­bined with ra­di­a­tion failed to sig­nif­i­cant­ly im­prove the over­all sur­vival rate of glioblas­toma pa­tients com­pared to a con­trol group re­ceiv­ing chemo plus ra­di­a­tion.

As usu­al, re­searchers will hold back the da­ta for a fu­ture con­fer­ence, but Check­Mate-498 is an­oth­er write-off.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER